Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Groundbreaking Test Monitors Radiation Therapy Toxicity in Cancer Patients

By LabMedica International staff writers
Posted on 18 Mar 2024
Print article
Image: The DiaCarta RadTox Test is intended to offer an early assessment of patient response to treatment (Photo courtesy of DiaCarta)
Image: The DiaCarta RadTox Test is intended to offer an early assessment of patient response to treatment (Photo courtesy of DiaCarta)

The concentration of circulating cell-free DNA (cfDNA) in the bloodstream is an important indicator that can help track how well cancer treatments are working. Before starting treatment, measuring cfDNA levels can give doctors a snapshot of the extent of the cancer’s spread in the body. High levels of cfDNA often mean the cancer is widespread or aggressive. As treatment goes on, doctors can keep an eye on cfDNA levels to see if the treatment is effective. A drop in cfDNA levels could mean the treatment is working and the tumor is getting smaller. But if cfDNA levels remain unchanged or rise, it might mean the treatment isn't working, and the cancer is still growing or has become resistant to treatment. Now, a simple blood test monitors this liquid biomarker in real time to track how well a cancer treatment is working.

DiaCarta’s (Pleasanton, CA, USA) RadTox Test is a liquid biopsy test designed to monitor tumor response and progression by observing changes in cfDNA levels. This test is crucial for determining early on if a patient's treatment plan is effective, helping avoid unnecessary side effects. The RadTox Test uses DiaCarta's unique QuantiDNA Direct cfDNA Test technology to measure cfDNA concentrations in a blood sample without the need for sample purification. This method allows doctors to quickly assess how well a treatment is working. With this information, doctors can adjust treatments in a more accurately and timely manner than before.

The RadTox Test is particularly useful during various treatments, including radiation, chemotherapy, immunotherapy, and other cancer therapies, monitoring cfDNA levels throughout the entire course of treatment. This provides early insights into how the cancer is responding to treatment, well before imaging tests might show changes, often three months after therapy starts. This timely feedback is crucial for making informed treatment decisions. Unlike traditional molecular residual disease (MRD) monitoring that only look for specific cancer mutations after treatment, the RadTox Test offers a broader perspective by tracking overall cfDNA changes. This gives doctors a clearer understanding of the treatment's impact, helping tailor care to each patient's needs.

"With just 10 microliters of plasma, our test has generated significant clinical data across a broad spectrum of cancer treatments," explained Dr. Aiguo (Adam) Zhang, President, and CEO of DiaCarta. "Our initial findings across 22 tumor types with over 250,000 samples performed globally demonstrate the immense potential of this pan-cancer monitoring test."

Gold Member
Chagas Disease Test
CHAGAS Cassette
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Epstein-Barr Virus Test
Mononucleosis Rapid Test
New
Luteinizing Hormone Assay
DRG LH-Serum ELISA Kit

Print article

Channels

Clinical Chemistry

view channel
Image: The tiny clay-based materials can be customized for a range of medical applications (Photo courtesy of Angira Roy and Sam O’Keefe)

‘Brilliantly Luminous’ Nanoscale Chemical Tool to Improve Disease Detection

Thousands of commercially available glowing molecules known as fluorophores are commonly used in medical imaging, disease detection, biomarker tagging, and chemical analysis. They are also integral in... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Delivers Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Pathology

view channel
Image: The ready-to-use DUB enzyme assay kits accelerate routine DUB activity assays without compromising data quality (Photo courtesy of Adobe Stock)

Sensitive and Specific DUB Enzyme Assay Kits Require Minimal Setup Without Substrate Preparation

Ubiquitination and deubiquitination are two important physiological processes in the ubiquitin-proteasome system, responsible for protein degradation in cells. Deubiquitinating (DUB) enzymes contain around... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.